![](/images/graphics-bg.png)
Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis
Joint Authors
Balijepalli, Chakrapani
Druyts, Eric
Zoratti, Michael J.
Wu, Ping
Kanji, Salmaan
Rabheru, Kiran
Yan, Kevin
Thorlund, Kristian
Source
Schizophrenia Research and Treatment
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-04-01
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
Treatment of schizophrenia with first- and second-generation antipsychotics has been associated with elevated prolactin levels, which may increase the risk for prolactin-related adverse events.
Methods.
Randomized controlled trials (RCTs) included in a recent systematic review were considered for this analysis.
A Bayesian network meta-analysis was used to compare changes in prolactin levels in pediatric patients diagnosed with schizophrenia or schizophrenia spectrum disorders treated with second-generation antipsychotics (SGAs).
Results.
Five RCTs, including 989 patients combined, have evaluated the changes in prolactin for pediatric patients after 6 weeks of treatment with risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone.
In the overall study population, treatment with risperidone was associated with the highest increase in mean prolactin levels compared to other SGAs.
Patients treated with risperidone 4–6 mg/day were found to experience the greatest increases (55.06 ng/ml [95% CrI: 40.53–69.58]) in prolactin levels, followed by risperidone 1–3 mg/day, paliperidone 3–6 mg/day, and paliperidone 6–12 mg/day.
Conclusions.
This study shows that there are differences in SGAs ability to cause hyperprolactinemia.
Further, there is clear evidence of safety concerns with risperidone and paliperidone treatment in adolescent schizophrenia patients.
Registration.
PROSPERO CRD42014009506.
American Psychological Association (APA)
Balijepalli, Chakrapani& Druyts, Eric& Zoratti, Michael J.& Wu, Ping& Kanji, Salmaan& Rabheru, Kiran…[et al.]. 2018. Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis. Schizophrenia Research and Treatment،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1213038
Modern Language Association (MLA)
Balijepalli, Chakrapani…[et al.]. Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis. Schizophrenia Research and Treatment No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1213038
American Medical Association (AMA)
Balijepalli, Chakrapani& Druyts, Eric& Zoratti, Michael J.& Wu, Ping& Kanji, Salmaan& Rabheru, Kiran…[et al.]. Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis. Schizophrenia Research and Treatment. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1213038
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1213038